DNA Link, Inc.

A127120

KR7127120004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
2,565 ^KRW	-5.18%		-6.39%	-12.01%

22/05	Orbitech Co., Ltd. agreed to acquire additional 8.56% stake in DNA Link, Inc. from Lee Jong Eun and Entermedia Co.,Ltd. for KRW 7.8 billion.	CI
25/01	DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd.	CI

Entermedia Co.,Ltd. announced that it has received KRW 6 billion in funding from DNA Link, Inc.

May 17, 2022

On May 17, 2022, Entermedia Co.,Ltd. closed the transaction. The transaction included participation from DNA Link, Inc.

Latest news about DNA Link, Inc.

Orbitech Co., Ltd. agreed to acquire additional 8.56% stake in DNA Link, Inc. from Lee Jong Eun and Entermedia Co.,Ltd. for KRW 7.8 billion.	22/05	CI
DNA Link, Inc. announced that it has received KRW 2 billion in funding from Orbitech Co., Ltd.	25/01	CI
DNA Link, Inc. announced that it has received KRW 5.000000096 billion in funding from Orbitech Co., Ltd.	13/11	CI
DNA Link, Inc. announced that it expects to receive KRW 15 billion in funding from Deokcheon Co., Ltd. and other investors	25/23/25	CI
DNA Link, Inc. announced that it expects to receive KRW 5.000001012 billion in funding from Orbitech Co., Ltd.	25/23/25	CI
SomaLogic Inc. and DNA Link Partners to Bring the 7,000-Plex Somascan Platform to the Fast-Growing Asia-Pacific Proteomics Market	20/23/20	CI
DNA Link, Inc. cancelled the transaction announced on May 2, 2023	07/23/07	CI
DNA Link, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
DNA Link to Raise 20 Billion Won From Share Sale; Shares Rise 3%	03/23/03	MT
DNA Link, Inc. announced that it expects to receive KRW 20.00000167 billion in funding	02/23/02	CI
DNA Link, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
DNA Link, Inc. entered into agreement to acquire 40% stake in National Bitumen Corporation for KRW9.6 billion.	30/22/30	CI
Entermedia Co.,Ltd. announced that it has received KRW 6 billion in funding from DNA Link, Inc.	17/22/17	CI
DNA Link, Inc. announced that it has received KRW 2.1 billion in funding from Entermedia Co.,Ltd.	17/22/17	CI
Entermedia Co.,Ltd. announced that it expects to receive KRW 6 billion in funding	22/22/22	CI
DNA Link, Inc. announced that it expects to receive KRW 2.1 billion in funding from Entermedia Co.,Ltd.	22/22/22	CI
DNA Link, Inc. agreed to acquire Entermedia Co.,Ltd. for KRW 4.9 billion.	15/22/15	CI
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test act the Point of Care	27/20/27	CI
DNA Link, Inc. announced that it has received KRW 7 billion in funding from Shinhan Capital Co., Ltd.	11/19/11	CI
DNA Link, Inc. announced that it expects to receive KRW 8 billion in funding from Shinhan Capital Co., Ltd.	07/19/07	CI
DNA Link, Inc. announced that it has received KRW 2.1 billion in funding from Balancers Co., Ltd., Eugene Investment & Securities Co., Ltd.	27/18/27	CI
DNA Link, Inc. announced that it expects to receive KRW 4 billion in funding from Balancers Co., Ltd., Eugene Investment & Securities Co.,Ltd.	10/18/10	CI
DNA Link, Inc. announced that it has received KRW 7 billion in funding from Synergy IB Investment Co., Ltd.	12/18/12	CI
DNA Link, Inc. completed the acquisition of L&C Bio Co., Ltd. from Hyungseok Choi and Myunghee Jung.	12/18/12	CI
DNA Link, Inc. announced that it expects to receive KRW 7 billion in funding from Synergy IB Investment Co., Ltd.	10/18/10	CI

DNA LINK, INC. is a Korea-based company engaged in the genetics research business. The Company provides genome biomarkers excavation products through integrated genomic analysis and integrated clinical information analysis including high-quality data products according to genomic analysis, interpretation of analysis results, and technologies of molecular diagnostic kit production under the brand name of enhanced genome integration system (EGIS). The Company also provides personal genome analysis service products under the brand name of deoxyribonucleic acid personalized services (DNAGPS).

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DNA LINK, INC.	-12.01%	35.23M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+44.98%	40.47B
CELLTRION, INC.	-10.87%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B